In a column for The Washington Post published on November 7, infectious disease clinician Alan Cross and retired senior executive Brian J. Morra argue that vaccines offer the most effective defense against the growing crisis of antibiotic-resistant bacterial infections.
“Bacteria are beating antibiotics. The government can't stand by,” Ara Darzi's Nov. 7 op-ed pointed out the threats caused by bacteria that are resistant to many of the most commonly used antibiotics. Pharmaceutical companies frequently abandon the antibiotic market because revenues fail to cover development costs, according to the op-ed. However, the authors argue that novel economic reforms proposed by earlier commentators fall short of resolving the underlying market failure.
Historical data shows that antibiotic resistance genes existed in bacteria isolated from 30,000-year-old permafrost sediments, long before modern antibiotics were invented. Consequently, even newly developed drugs will eventually lose efficacy as pathogens adapt. The authors contend that preventing infections altogether through vaccination remains the most reliable strategy to curb resistance.
Successful precedents exist in public health administration. Haemophilus influenzae type B infections, once a major cause of pediatric morbidity and mortality, became rare in the United States after the introduction of an effective vaccine. Similarly, targeted immunization virtually eliminated epidemic meningococcal infections across sub-Saharan Africa.
Despite many vaccines in development driven by advances in basic science, current government policies and research funding cuts threaten progress. The authors assert that funding for vaccine development must be restored to contain the ongoing antibiotic-resistance crisis.
- Antibiotic Resistance: Bacteria naturally evolve defense mechanisms against drugs, rendering treatments ineffective over time regardless of how new the medication is.
- Prevention Over Treatment: Vaccines stop bacterial infections before they start, reducing the overall need for antibiotics and slowing down drug resistance.
- Market Failures: Developing new antibiotics is financially difficult for drug companies, shifting the public health burden toward preventative measures like vaccines.
The commentary emphasizes that basic science has created many vaccines in development, but government policy shifts jeopardize these scientific gains. Research support reductions directly impact the development of immunizations needed to protect against drug-resistant strains.
Without sustained financial backing, the research community cannot advance candidate vaccines through critical preclinical and clinical phases. The authors call for immediate restoration of government funding to ensure public health infrastructure can outpace microbial adaptation.
| Intervention | Target Condition | Public Health Impact |
|---|---|---|
| Hib Vaccine | Haemophilus influenzae type B | Became rare in the United States after the introduction of an effective vaccine |
| Meningococcal Vaccine | Epidemic Meningitis | Virtually eliminated epidemic infections in sub-Saharan Africa |
| Future Vaccines | Antibiotic-Resistant Pathogens | Proposed defense mechanism to prevent infections requiring failing antibiotics |
- Cross, A., & Morra, B. J. The writers, an infectious disease clinician and a retired senior executive, wrote a letter to The Washington Post.
